Skip to main content

Table 4 Mean costs and QALYs to 24 months post-randomisation

From: Clinical and cost-effectiveness analysis of an open label, single-centre, randomised trial of spinal cord stimulation (SCS) versus percutaneous myocardial laser revascularisation (PMR) in patients with refractory angina pectoris: The SPiRiT trial

Resource

SCS (n = 34)

Mean cost per patient (95% CI)

PMR (n = 34)

Mean cost per patient (95% CI)

Mean cost difference

(95% CI)

PMR/SCS Equipment*

£8,239

£5,755

 

PMR/SCS Procedure

£4,353 (£4,046 to £4,397)

£326 (£307 to £353)

 

PMR/SCS LOS

£756 (£685 to £872)

£812 (£695 to £988)

 

Total SCS/PMR procedure cost

£13,350 (£13,112 to £13,491)

£6,892 (£6,757 to £7,087)

£6,459 (£6,196 to £6,642) †

Non-procedural cost

£957 (£839 to £1,088)

£1,025 (£891 to £1,147)

 

Cardiac-related medication

£3,294 (£2,076 to £5,844)

£3,645 (£1,638 to £7,537)

 

Cardiac inpatient episodes

£97 (£22 to £281)

£146 (£18 to £492)

 

Non-cardiac inpatient episodes

£4,350 (£3,064 to £6,873)

£4,811 (£2,750 to £8,633)

 

Total non-procedural costs

  

-£461 (-£4,399 to £1,964) ‡

Overall treatment costs at 24 months**

£17,736 (£16,398 to £19,202)

£12,215 (£9,603 to £15,448)

£5,520 (£1,966 to £8,613)†

Utility

SCS (n = 34)

PMR (n = 34)

QALY difference

 

Mean QALY per patient (95% CI)

Mean QALY per patient (95% CI)

(95% CI)

QALYs up to 24 months**

1.19 (1.040 to 1.319)

1.07 (0.960 to 1.178)

0.12 (-0.04 to 0.30)‡

  1. *Fixed cost applied to all patients; **Overall costs and QALYs taking account of censoring; † p < 0.01; ‡ p > 0.1